Zhen Su, CEO and Entrepreneur at Marengo Therapeutics, shared a post on LinkedIn:
“We are grateful for the opportunity to present our company at the 2026 J.P. Morgan Annual Healthcare Conference private track.
We look forward to an exciting year ahead—bringing renewed hope to cancer patients and advancing opportunities to transform cancer care. In 2026, we aim to complete two Phase 2a clinical trials to unlock the broad potential of Invika as a next-generation immuno-oncology backbone, particularly for patients with PD-1–resistant or refractory cancers.
We have a winning team at Marengo and I am confident that we will prevail and succeed in 2026!”
More posts featuring Zhen Su.
